-
2023-504151-27-00
5
2024-05-09
Psychosis associated with Alzheimer’s Disease
-
2023-510506-41-00
4
2024-04-15
Locally advanced, unresectable non-small-cell lung cancer (NSCLC)
(Sta
-
2023-505141-48-00
5
2024-03-07
Fibrosis
-
2022-502113-28-00
5
2024-02-01
Follicular lymphoma
-
2023-503938-52-00
4
2024-01-26
Progressive Glioblastoma
-
2022-502980-39-00
5
2024-01-25
Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
-
2022-501831-18-00
4
2023-09-13
Patients with hematologic malignancies and undergoing allogenic hemato
-
2024-512320-11-00
5
2023-08-09
Primary diffuse large B-cell lymphoma of the central nervous system
(P
-
2024-517966-40-00
4
2023-07-13
Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::ABL1 positive (Ph
-
2022-502415-11-00
5
2023-06-16
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
-
2022-501808-96-00
4
2023-05-15
Mantle Cell Lymphoma
-
2022-501187-18-00
5
2023-04-24
a. Diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS)
-
2022-500783-35-00
5
2022-12-06
Acute Myeloid Leukemia
-
2022-500764-35-00
6
2022-10-13
Patients with advanced HER2-negative, hormone receptor positive (HER2n
-
2023-503335-18-00
1
2022-07-29
Chronic myeloid leukemia
-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma
-
2023-504599-10-00
4
2022-03-29
Chronic lymphocytic leukemia recurrent
-
2024-512174-10-00
5
2021-11-11
metastatic colorectal cancer
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre
-
2023-509863-26-00
11
2021-04-29
Liver cirrhosis
-
2024-510616-73-00
5
2020-12-16
newly diagnosed WHO grade 2 or 3 glioma
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2023-509846-36-00
9
2020-05-29
Advanced Solid Tumors
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)